Sichuan Kelun Pharmaceutical Co Ltd 2024 SR
The report details Kelun Pharma's ESG performance for 2024, highlighting its "Three Driving Engines and Innovative Growth" strategy. Key achievements include a 19.53% increase in net profit and a 11.20% rise in R&D investment, reaching RMB 2.17 billion. The company advanced its Antibody-Coupled Drugs (ADC) R&D platform and expanded its product accessibility in over 50 countries. Environmentally, it invested RMB 661.40 million in protection and achieved a "BB" MSCI ESG rating. Socially, it maintained 100% social security coverage for its 21,864 employees and donated approximately RMB 57 million to public welfare.
Company: Sichuan Kelun Pharmaceutical Co Ltd
Sector: Health Care
Country: China
Year: 2024
Type: SR
Pages: 73
Sichuan Kelun Pharmaceutical Co Ltd
ESG Report
The report details Kelun Pharma's ESG performance for 2024, highlighting its "Three Driving Engines and Innovative Growth" strategy. Key achievements include a 19.53% increase in net profit and a 11.20% rise in R&D investment, reaching RMB 2.17 billion. The company advanced its Antibody-Coupled Drugs (ADC) R&D platform and expanded its product accessibility in over 50 countries. Environmentally, it invested RMB 661.40 million in protection and achieved a "BB" MSCI ESG rating. Socially, it maintained 100% social security coverage for its 21,864 employees and donated approximately RMB 57 million to public welfare.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees